T1	CHEM 44 52	Avelumab
#1	AnnotatorNotes T1	C4055417; avelumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T2	DISO 72 103	cáncer de pulmón no microcítico
#2	AnnotatorNotes T2	C0007131; Non-Small Cell Lung Carcinoma; Neoplastic Process
T3	CHEM 106 114	Avelumab
#3	AnnotatorNotes T3	C4055417; avelumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T4	CHEM 172 204	anticuerpo monoclonal anti-PD-L1
T5	CHEM 295 306	MSB0010718C
#4	AnnotatorNotes T5	C3896806; MSB0010718C; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T6	PROC 238 281	Ensayo de fase III, abierto y multicéntrico
T7	CHEM 285 293	avelumab
#5	AnnotatorNotes T7	C4055417; avelumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T8	CHEM 318 345	doblete con base de platino
#6	AnnotatorNotes T8	C5206469; Platinum Doublet; Pharmacologic Substance
T9	PROC 351 379	tratamiento de primera línea
#7	AnnotatorNotes T9	C1708063; First line treatment; Therapeutic or Preventive Procedure
T10	DISO 384 415	cáncer de pulmón no microcítico
#8	AnnotatorNotes T10	C0007131; Non-Small Cell Lung Carcinoma; Neoplastic Process
T11	DISO 490 506	cáncer de pulmón
#9	AnnotatorNotes T11	C0242379; Malignant neoplasm of lung; Neoplastic Process | C0684249; Carcinoma of lung; Neoplastic Process
T12	PROC 786 793	tinción
#10	AnnotatorNotes T12	C0487602; Staining method; Laboratory Procedure
T13	CHEM 690 696	formol
#11	AnnotatorNotes T13	C0016584; Formol; Organic Chemical · Hazardous or Poisonous Substance | C0949307; formalin; Organic Chemical · Pharmacologic Substance · Hazardous or Poisonous Substance
T14	CHEM 711 719	parafina
#12	AnnotatorNotes T14	C0030415; paraffin; Organic Chemical · Pharmacologic Substance
T15	ANAT 723 737	tejido tumoral
T16	DISO 776 781	tumor
#13	AnnotatorNotes T16	C0006826; Malignant Neoplasms; Neoplastic Process | C0027651; Neoplasms; Neoplastic Process | C0577559; Mass of body structure; Finding
T17	DISO 817 831	lesión medible
T18	DISO 835 851	CPNM metastásico
T19	PROC 937 958	tratamiento sistémico
T20	DISO 967 983	cáncer de pulmón
#14	AnnotatorNotes T20	C0242379; Malignant neoplasm of lung; Neoplastic Process | C0684249; Carcinoma of lung; Neoplastic Process
T21	DISO 1180 1199	CPNM no epidermoide
T22	PROC 1316 1327	tratamiento
#15	AnnotatorNotes T22	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T23	CHEM 1349 1359	anticuerpo
#16	AnnotatorNotes T23	C0003241; Antibodies; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T24	CHEM 1362 1369	fármaco
#17	AnnotatorNotes T24	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T25	CHEM 1385 1429	proteínas correguladoras de los linfocitos T
T26	ANAT 1417 1429	linfocitos T
#18	AnnotatorNotes T26	C0039194; T-Lymphocyte; Cell
T27	PROC 1431 1471	tratamiento concurrente contra el cáncer
T28	DISO 1465 1471	cáncer
#19	AnnotatorNotes T28	C0006826; Malignant Neoplasms; Neoplastic Process
T29	CHEM 1474 1490	inmunosupresores
#20	AnnotatorNotes T29	C0021081; Immunosuppressive Agents; Immunologic Factor · Pharmacologic Substance
T30	DISO 1516 1533	hipersensibilidad
#21	AnnotatorNotes T30	C0020517; Hypersensitivity; Pathologic Function | C0429891; Hypersensitivity finding; Finding
T31	CHEM 1546 1570	anticuerpos monoclonales
#22	AnnotatorNotes T31	C0003250; Monoclonal Antibodies; Amino Acid, Peptide, or Protein · Immunologic Factor
T32	DISO 1630 1640	anafilaxia
#23	AnnotatorNotes T32	C0002792; anaphylaxis; Disease or Syndrome
T33	DISO 1643 1647	asma
#24	AnnotatorNotes T33	C0004096; Asthma; Disease or Syndrome
T34	DISO 1704 1708	asma
#25	AnnotatorNotes T34	C0004096; Asthma; Disease or Syndrome
T35	DISO 1736 1747	toxicidades
#26	AnnotatorNotes T35	C0600688; Toxic effect; Injury or Poisoning
T36	PROC 1778 1790	tratamientos
#27	AnnotatorNotes T36	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T37	DISO 1883 1902	metástasis cerebral
#28	AnnotatorNotes T37	C0220650; Metastatic malignant neoplasm to brain; Neoplastic Process | C0555278; Cerebral metastasis; Neoplastic Process
T38	DISO 1961 1982	metástasis cerebrales
#29	AnnotatorNotes T38	C0220650; Metastatic malignant neoplasm to brain; Neoplastic Process | C0555278; Cerebral metastasis; Neoplastic Process
T39	CHEM 2123 2133	esteroides
#30	AnnotatorNotes T39	C0038317; Steroids; Organic Chemical · Pharmacologic Substance
T40	CHEM 2218 2228	prednisona
#31	AnnotatorNotes T40	C0032952; prednisone; Hormone · Organic Chemical · Pharmacologic Substance
T41	DISO 2265 2286	síntomas neurológicos
#32	AnnotatorNotes T41	C0235031; Neurologic Symptoms; Sign or Symptom
T42	DISO 2345 2369	enfermedad en el cerebro
T43	ANAT 82 88	pulmón
#33	AnnotatorNotes T43	C0024109; Lung; Body Part, Organ, or Organ Component | C1278908; Entire lung; Body Part, Organ, or Organ Component
T44	ANAT 92 103	microcítico
#34	AnnotatorNotes T44	C1514085; Neoplastic Small Cell; Cell | C1518241; Malignant Small Cell; Cell
T45	CHEM 205 216	MSB0010718C
#35	AnnotatorNotes T45	C3896806; MSB0010718C; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T46	ANAT 394 400	pulmón
#36	AnnotatorNotes T46	C0024109; Lung; Body Part, Organ, or Organ Component | C1278908; Entire lung; Body Part, Organ, or Organ Component
T47	ANAT 404 415	microcítico
#37	AnnotatorNotes T47	C1514085; Neoplastic Small Cell; Cell | C1518241; Malignant Small Cell; Cell
T48	ANAT 500 506	pulmón
#38	AnnotatorNotes T48	C0024109; Lung; Body Part, Organ, or Organ Component | C1278908; Entire lung; Body Part, Organ, or Organ Component
T49	ANAT 671 678	biopsia
#39	AnnotatorNotes T49	C0677862; Biopsy sample; Tissue
T50	DISO 730 737	tumoral
#40	AnnotatorNotes T50	C0006826; Malignant Neoplasms; Neoplastic Process | C0027651; Neoplasms; Neoplastic Process | C0577559; Mass of body structure; Finding
T51	PROC 881 891	histología
#41	AnnotatorNotes T51	C0344441; Histology Procedure; Laboratory Procedure
T52	ANAT 977 983	pulmón
#42	AnnotatorNotes T52	C0024109; Lung; Body Part, Organ, or Organ Component | C1278908; Entire lung; Body Part, Organ, or Organ Component
T53	DISO 1127 1137;1150 1162	mutaciones del gen EGFR
#43	AnnotatorNotes T53	C3266992; EGFR gene mutation; Cell or Molecular Dysfunction
T54	PROC 1983 1991	tratadas
#44	AnnotatorNotes T54	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T55	DISO 1492 1502	reacciones
#45	AnnotatorNotes T55	C0041755; Adverse reaction to drug; Pathologic Function | C0559546; Adverse reactions; Pathologic Function | C0879626; Adverse effects; Pathologic Function
T56	ANAT 1894 1902	cerebral
#46	AnnotatorNotes T56	C0242202; Cerebrum; Body Part, Organ, or Organ Component | C1269537; Entire brain; Body Part, Organ, or Organ Component | C1280654; Entire cerebrum; Body Part, Organ, or Organ Component
T57	ANAT 1972 1982	cerebrales
#47	AnnotatorNotes T57	C0242202; Cerebrum; Body Part, Organ, or Organ Component | C1269537; Entire brain; Body Part, Organ, or Organ Component | C1280654; Entire cerebrum; Body Part, Organ, or Organ Component
T58	ANAT 2362 2369	cerebro
#48	AnnotatorNotes T58	C0242202; Cerebrum; Body Part, Organ, or Organ Component | C1269537; Entire brain; Body Part, Organ, or Organ Component | C1280654; Entire cerebrum; Body Part, Organ, or Organ Component
T59	Date 12 16	2015
T60	Neg_cue 89 91	no
T61	Neg_cue 401 403	no
T63	LIVB 545 552	Hombres
#49	AnnotatorNotes T63	C0025266; Male population group; Population Group
T64	LIVB 555 562	mujeres
#50	AnnotatorNotes T64	C0043210; Woman; Population Group
T65	Age 563 582	a partir de 18 años
T67	Neg_cue 782 785	sin
T68	LIVB 897 904	sujetos
#51	AnnotatorNotes T68	C0681850; Study Subject; Group
T70	Neg_cue 930 936	ningún
T71	Duration 1027 1048	superior a 12 semanas
T72	Neg_cue 1088 1090	No
T74	LIVB 1105 1137	sujetos portadores de mutaciones
#52	AnnotatorNotes T74	C0681850; Study Subject; Group + C2985478; Mutation Carrier; Population Group
T75	GENE 1154 1162	gen EGFR
#53	AnnotatorNotes T75	C1414313; EGFR gene; Gene or Genome
T76	Neg_cue 1164 1166	ni
T78	GENE 1231 1270	gen de la cinasa del linfoma anaplásico
#54	AnnotatorNotes T78	C1332080; ALK gene; Gene or Genome
T79	Neg_cue 1853 1864	Se excluirá
T80	LIVB 1871 1878	sujetos
#55	AnnotatorNotes T80	C0681850; Study Subject; Group
T82	Duration 2040 2058	al menos 2 semanas
T83	LIVB 2085 2092	sujetos
#56	AnnotatorNotes T83	C0681850; Study Subject; Group
T84	Dose 2164 2181	una dosis estable
T85	Dose 2199 2206	< 10 mg
T86	Frequency 2207 2214	diarios
T87	Neg_cue 2252 2254	no
T89	LIVB 2426 2440	monitor médico
#57	AnnotatorNotes T89	C1708968; Medical Monitor; Professional or Occupational Group
T90	GENE 1272 1275	ALK
#58	AnnotatorNotes T90	C1332080; ALK gene; Gene or Genome
T62	PROC 416 421	PD-L1
#59	AnnotatorNotes T62	C4722206; Programmed Death Ligand 1 Measurement; Laboratory Procedure
T66	PROC 798 803	PD-L1
#60	AnnotatorNotes T66	C4722206; Programmed Death Ligand 1 Measurement; Laboratory Procedure
T69	Neg_cue 1297 1306	exclusión
T73	PROC 2107 2122	dejado de tomar
#61	AnnotatorNotes T73	C0850893; stop medication; Therapeutic or Preventive Procedure (?)
A1	Assertion T74 Negated
A2	Assertion T21 Negated
A3	Assertion T80 Negated
A4	Assertion T37 Negated
A5	Assertion T41 Negated
A6	Assertion T44 Negated
A7	Assertion T47 Negated
A8	Assertion T12 Negated
A9	Assertion T19 Negated
A10	Assertion T22 Negated
A11	Assertion T23 Negated
A12	Assertion T24 Negated
A13	Assertion T27 Negated
A14	Assertion T29 Negated
A15	Assertion T55 Negated
A16	Assertion T30 Negated
A17	Assertion T32 Negated
A18	Assertion T33 Negated
A19	Assertion T35 Negated
#62	AnnotatorNotes T6	C0282461; Phase 3 Clinical Trials; Research Activity + C1709323; Open Label Study; Research Activity + C1096776; Multicenter Study; Research Activity
#63	AnnotatorNotes T4	C4289971; Anti-PD-L1 Monoclonal Antibody; Amino Acid, Peptide, or Protein · Pharmacologic Substance · Immunologic Factor 
#64	AnnotatorNotes T17	C5238366; Measurable Lesion; Finding 
#65	AnnotatorNotes T18	C0278987; Metastatic non-small cell lung cancer; Neoplastic Process 
#66	AnnotatorNotes T15	C0475358; Tumor tissue sample; Tissue
#67	AnnotatorNotes T21	C4324656; Non-squamous non-small cell lung cancer; Neoplastic Process 
#68	AnnotatorNotes T42	C0006111; Brain Diseases; Disease or Syndrome | C0085584; Encephalopathies; Disease or Syndrome
T77	Neg_cue 1185 1187	no
T81	ANAT 1188 1199	epidermoide
A20	Assertion T81 Negated
R1	Negation Arg1:T60 Arg2:T44	
R2	Negation Arg1:T61 Arg2:T47	
R3	Negation Arg1:T67 Arg2:T12	
R4	Negation Arg1:T70 Arg2:T19	
R5	Negation Arg1:T72 Arg2:T74	
R6	Negation Arg1:T76 Arg2:T21	
R7	Negation Arg1:T77 Arg2:T81	
T88	Observation 1214 1276	reordenación del gen de la cinasa del linfoma anaplásico (ALK)
#69	AnnotatorNotes T88	C4688368; ALK Gene Rearrangement; Finding
A21	Assertion T88 Negated
R8	Negation Arg1:T76 Arg2:T88	
A22	Assertion T53 Negated
R10	Negation Arg1:T72 Arg2:T53	
R11	Negation Arg1:T69 Arg2:T22	
R12	Negation Arg1:T69 Arg2:T23	
R13	Negation Arg1:T69 Arg2:T24	
R14	Used_for Arg1:T23 Arg2:T22	
R15	Used_for Arg1:T24 Arg2:T22	
R16	Negation Arg1:T69 Arg2:T27	
R17	Negation Arg1:T69 Arg2:T29	
R18	Negation Arg1:T69 Arg2:T55	
R19	Negation Arg1:T69 Arg2:T30	
A23	Status T55 History_of
A24	Status T30 History_of
T91	Quantifier_or_Qualifier 1534 1539	grave
A25	Assertion T91 Negated
#70	AnnotatorNotes T91	C1547227; Severe - Severity of Illness Code; Intellectual Product
R20	Has_Quantifier_or_Qualifier Arg1:T30 Arg2:T91	
R21	Negation Arg1:T69 Arg2:T91	
R22	Negation Arg1:T69 Arg2:T32	
A26	Status T32 History_of
R23	Negation Arg1:T69 Arg2:T33	
A27	Status T33 History_of
T92	Quantifier_or_Qualifier 1648 1661	incontrolable
A28	Assertion T92 Negated
R24	Has_Quantifier_or_Qualifier Arg1:T33 Arg2:T92	
R25	Negation Arg1:T69 Arg2:T92	
T93	Quantifier_or_Qualifier 1709 1732	parcialmente controlado
A29	Assertion T93 Negated
A30	Assertion T34 Negated
R26	Has_Quantifier_or_Qualifier Arg1:T34 Arg2:T93	
T94	Quantifier_or_Qualifier 1677 1703	3 o más características de
A31	Assertion T94 Negated
R27	Has_Quantifier_or_Qualifier Arg1:T34 Arg2:T94	
R28	Negation Arg1:T69 Arg2:T34	
R29	Negation Arg1:T69 Arg2:T94	
R30	Negation Arg1:T69 Arg2:T93	
T95	Quantifier_or_Qualifier 1748 1760	persistentes
A32	Assertion T95 Negated
#71	AnnotatorNotes T95	C0205322; Persistent; Temporal Concept
R31	Has_Quantifier_or_Qualifier Arg1:T35 Arg2:T95	
R32	Negation Arg1:T69 Arg2:T35	
R33	Negation Arg1:T69 Arg2:T95	
T96	Result_or_Value 1805 1814	grado > 1
A33	Assertion T96 Negated
A34	Status T36 History_of
R35	Negation Arg1:T69 Arg2:T96	
R36	Negation Arg1:T79 Arg2:T80	
R37	Experiences Arg1:T80 Arg2:T37	
R38	Negation Arg1:T79 Arg2:T37	
R39	Negation Arg1:T87 Arg2:T41	
T97	Quantifier_or_Qualifier 2287 2298	continuados
A35	Assertion T97 Negated
#72	AnnotatorNotes T97	C0549178; Continuous; Idea or Concept
R40	Has_Quantifier_or_Qualifier Arg1:T41 Arg2:T97	
R41	Negation Arg1:T87 Arg2:T97	
T98	Spec_cue 2381 2389	posibles
T99	CONC 2390 2401	excepciones
A36	Assertion T99 Speculated
#73	AnnotatorNotes T99	C1705847; Exception - Property or Attribute; Conceptual Entity
R43	Speculation Arg1:T98 Arg2:T99	
T100	Quantifier_or_Qualifier 54 67	primera línea
R44	Has_Quantifier_or_Qualifier Arg1:T1 Arg2:T100	
R45	Location_of Arg1:T43 Arg2:T2	
R46	Used_for Arg1:T7 Arg2:T9	
R47	Used_for Arg1:T5 Arg2:T9	
R48	Used_for Arg1:T8 Arg2:T9	
R49	Location_of Arg1:T46 Arg2:T10	
T101	Observation 423 433	recurrente
#74	AnnotatorNotes T101	C0679254; Disease recurrence; Finding
R51	Has_Quantifier_or_Qualifier Arg1:T10 Arg2:T101	
T102	Quantifier_or_Qualifier 439 449	estadio IV
R52	Has_Quantifier_or_Qualifier Arg1:T10 Arg2:T102	
R53	Has_Age Arg1:T63 Arg2:T65	
R54	Has_Age Arg1:T64 Arg2:T65	
T103	CONC 591 595	ECOG
#75	AnnotatorNotes T103	C1520224; ECOG performance status; Intellectual Product
T104	Result_or_Value 596 607	entre 0 y 1
R55	Has_Result_or_Value Arg1:T103 Arg2:T104	
T105	CONC 611 633	incorporarse al ensayo
#76	AnnotatorNotes T105	C1512693; Inclusion; Qualitative Concept
R56	Overlap Arg1:T103 Arg2:T105	
T106	PROC 679 719	fijada con formol e incluida en parafina
#77	AnnotatorNotes T106	C4684951; Formalin-Fixed Paraffin-Embedded; Laboratory Procedure
R57	Used_for Arg1:T13 Arg2:T106	
R58	Used_for Arg1:T14 Arg2:T106	
T107	Quantifier_or_Qualifier 740 772	7 (preferentemente 10) secciones
R59	Has_Quantifier_or_Qualifier Arg1:T16 Arg2:T107	
T108	Quantifier_or_Qualifier 658 670	un bloque de
R60	Has_Quantifier_or_Qualifier Arg1:T49 Arg2:T108	
R61	Experiences Arg1:T63 Arg2:T50	
R62	Experiences Arg1:T63 Arg2:T16	
R63	Experiences Arg1:T64 Arg2:T50	
R64	Experiences Arg1:T64 Arg2:T16	
R65	Location_of Arg1:T15 Arg2:T12	
R66	Location_of Arg1:T49 Arg2:T12	
T109	Quantifier_or_Qualifier 806 816	al menos 1
R67	Has_Quantifier_or_Qualifier Arg1:T17 Arg2:T109	
R68	Causes Arg1:T18 Arg2:T17	
R69	Experiences Arg1:T63 Arg2:T17	
R70	Experiences Arg1:T63 Arg2:T18	
R71	Experiences Arg1:T63 Arg2:T51	
R72	Experiences Arg1:T64 Arg2:T17	
R73	Experiences Arg1:T64 Arg2:T18	
R74	Experiences Arg1:T64 Arg2:T51	
T110	Observation 854 865	recidivante
#78	AnnotatorNotes T110	C2825055; Recurrence (disease attribute); Pathologic Function
R75	Has_Quantifier_or_Qualifier Arg1:T18 Arg2:T110	
R79	Experiences Arg1:T68 Arg2:T19	
#79	AnnotatorNotes T19	C1515119; Systemic Therapy; Therapeutic or Preventive Procedure
R80	Location_of Arg1:T52 Arg2:T20	
R81	Experiences Arg1:T68 Arg2:T20	
T111	CONC 989 1006	esperanza de vida
#80	AnnotatorNotes T111	C0023671; Life Expectancy; Group Attribute
R82	Has_Duration_or_Interval Arg1:T111 Arg2:T71	
R83	Location_of Arg1:T75 Arg2:T53	
R84	Location_of Arg1:T81 Arg2:T21	
#81	AnnotatorNotes T81	C0221910; Squamous Epithelial Cells; Cell
R85	Location_of Arg1:T44 Arg2:T2	
R86	Location_of Arg1:T47 Arg2:T10	
R87	Location_of Arg1:T48 Arg2:T11	
T112	Quantifier_or_Qualifier 472 485	primera línea
R88	Location_of Arg1:T78 Arg2:T88	
R89	Location_of Arg1:T90 Arg2:T88	
R90	Experiences Arg1:T74 Arg2:T53	
R91	Experiences Arg1:T74 Arg2:T21	
R93	Experiences Arg1:T74 Arg2:T88	
R9	Overlap Arg1:T21 Arg2:T88	
R92	Causes Arg1:T31 Arg2:T55	
R94	Causes Arg1:T31 Arg2:T30	
T113	Result_or_Value 1575 1584	grado ≥ 3
T114	CONC 1598 1611	CTCAE del NCI
#82	AnnotatorNotes T114	C1516728; National Cancer Institute common terminology criteria for adverse events; Intellectual Product
R97	Has_Result_or_Value Arg1:T114 Arg2:T113	
#83	AnnotatorNotes T92	C0205318; Uncontrolled; Qualitative Concept
R95	Causes Arg1:T36 Arg2:T35	
T115	CONC 1838 1851	CTCAE del NCI
#84	AnnotatorNotes T115	C1516728; National Cancer Institute common terminology criteria for adverse events; Intellectual Product
R96	Has_Result_or_Value Arg1:T115 Arg2:T96	
R34	Location_of Arg1:T56 Arg2:T37	
R98	Location_of Arg1:T57 Arg2:T38	
R99	Experiences Arg1:T80 Arg2:T38	
R100	Experiences Arg1:T80 Arg2:T54	
T116	Observation 2010 2031	clínicamente estables
#85	AnnotatorNotes T116	C1282982; Patient's condition stable; Finding
R101	Experiences Arg1:T80 Arg2:T116	
R102	Has_Duration_or_Interval Arg1:T116 Arg2:T82	
T117	PROC 2068 2079	inscribirse
#86	AnnotatorNotes T117	C4041024; Enrollment in clinical trial; Research Activity
R103	Before Arg1:T116 Arg2:T117	
R104	Before Arg1:T54 Arg2:T117	
R105	Experiences Arg1:T83 Arg2:T73	
A37	Status T73 History_of
R106	Used_for Arg1:T39 Arg2:T73	
A38	Status T39 History_of
T118	CONC 2187 2198	disminución
#87	AnnotatorNotes T118	C0547047; Decrease; Quantitative Concept
R108	Has_Dose_or_Strength Arg1:T40 Arg2:T85	
R109	Has_Frequency Arg1:T40 Arg2:T86	
R110	Has_Dose_or_Strength Arg1:T40 Arg2:T84	
R107	Used_for Arg1:T40 Arg2:T73	
T119	CONC 2218 2228;2232 2243	prednisona equivalente
R111	Experiences Arg1:T83 Arg2:T40	
R112	Experiences Arg1:T83 Arg2:T41	
R113	Location_of Arg1:T58 Arg2:T42	
R42	Overlap Arg1:T41 Arg2:T42	
T120	PROC 2461 2472	inscribirse
R114	Before Arg1:T99 Arg2:T120	
#88	AnnotatorNotes T120	C4041024; Enrollment in clinical trial; Research Activity
T121	Observation 416 422	PD-L1+
#89	AnnotatorNotes T121	C4054275; PD-L1 Overexpression; Finding
R115	Overlap Arg1:T10 Arg2:T121	
T122	Observation 798 804	PD-L1+
#90	AnnotatorNotes T122	C4054275; PD-L1 Overexpression; Finding
R116	Overlap Arg1:T16 Arg2:T122	
T123	Quantifier_or_Qualifier 1370 1429	dirigido a las proteínas correguladoras de los linfocitos T
R117	Has_Quantifier_or_Qualifier Arg1:T23 Arg2:T123	
R118	Has_Quantifier_or_Qualifier Arg1:T24 Arg2:T123	
A39	Assertion T123 Negated
R119	Negation Arg1:T69 Arg2:T123	
R120	Has_Dose_or_Strength Arg1:T118 Arg2:T85	
R121	Overlap Arg1:T38 Arg2:T116	
#91	AnnotatorNotes T93	C3853135; Somewhat controlled; Functional Concept
A40	Experiencer T64 Patient
A41	Experiencer T63 Patient
A42	Experiencer T68 Patient
A43	Experiencer T74 Patient
A44	Experiencer T80 Patient
A45	Experiencer T83 Patient
A46	Experiencer T89 Other
R50	Has_Result_or_Value Arg1:T62 Arg2:T121	
